Ulinastatin as a neuroprotective and anti‐inflammatory agent in infant piglets model undergoing surgery on hypothermic low‐flow cardiopulmonary bypass

Infants are potentially more susceptible to brain injury mediated via cell death attributed to cardiopulmonary bypass (CPB) especially with prolonged hypothermic low flow (HLF). We hypothesized that a human urinary protease inhibitor (ulinastatin), by its anti‐inflammatory effect, would reduce central nervous system (CNS) injury during HLF.

[1]  Yong Fang,et al.  Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response. , 2011, The Journal of trauma.

[2]  Y. Li,et al.  Neuroprotection by Ulinastatin in Experimental Autoimmune Encephalomyelitis , 2011, Neurochemical Research.

[3]  V. Nadkarni,et al.  Effect of deep hypothermic circulatory arrest followed by low-flow cardiopulmonary bypass on brain metabolism in newborn piglets: Comparison of pH-stat and &agr;-stat management , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[4]  Yong-Guo Li,et al.  Effect of hyperbaric oxygen and ulinastatin on plasma endotoxin, soluble CD14, endotoxin-neutralizing capacity and cytokines in acute necrotizing pancreatitis. , 2010, Canadian journal of surgery. Journal canadien de chirurgie.

[5]  E. Kochs,et al.  The Impact of Cardiopulmonary Bypass on Systemic Interleukin-6 Release, Cerebral Nuclear Factor-kappa B Expression, and Neurocognitive Outcome in Rats , 2010, Anesthesia and analgesia.

[6]  K. Lee,et al.  The Anti-Inflammatory Effects of Ulinastatin in Trauma Patients with Hemorrhagic Shock , 2009, Journal of Korean medical science.

[7]  B. S. Zanutto,et al.  Differential gene expression in the rat hippocampus during learning of an operant conditioning task , 2009, Neuroscience.

[8]  Yu-min Li,et al.  Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. , 2009, Chinese medical journal.

[9]  P. Pastuszko,et al.  The effect of hypothermia on neuronal viability following cardiopulmonary bypass and circulatory arrest in newborn piglets. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  A. Sakamoto,et al.  Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction , 2006, Critical care medicine.

[11]  F. Sieber,et al.  Hippocampus bcl-2 and bax Expression and Neuronal Apoptosis After Moderate Hypothermic Cardiopulmonary Bypass in Rats , 2006, Anesthesia and analgesia.

[12]  T. Karamlou,et al.  Hypothermic low-flow cardiopulmonary bypass impairs pulmonary and right ventricular function more than circulatory arrest. , 2006, The Annals of thoracic surgery.

[13]  T. Yoshikawa,et al.  Protective Role of Urinary Trypsin Inhibitor in Acute Lung Injury Induced by Lipopolysaccharide , 2005, Experimental biology and medicine.

[14]  K. Ushijima,et al.  Neuroprotective Effect of Urinary Trypsin Inhibitor against Focal Cerebral Ischemia–Reperfusion Injury in Rats , 2003, Anesthesiology.

[15]  T. Sugita,et al.  Effect of a human urinary protease inhibitor (Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. , 2002, Journal of Cardiovascular Surgery.

[16]  T. Yau,et al.  Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[17]  J. Coselli,et al.  S100beta correlates with neurologic complications after aortic operation using circulatory arrest. , 2001, The Annals of thoracic surgery.

[18]  G. Asimakopoulos.  Mechanisms of the systemic inflammatory response , 1999, Perfusion.

[19]  J. Takeda,et al.  A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass. , 1997, Journal of cardiothoracic and vascular anesthesia.

[20]  T. Tanabe,et al.  [Effect of ulinastatin on the free radical during cardiopulmonary bypass]. , 1995, Masui. The Japanese journal of anesthesiology.

[21]  G. Holmes,et al.  Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary arrest , 1995 .

[22]  H. Lindberg,et al.  Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. , 1995, Scandinavian journal of clinical and laboratory investigation.

[23]  R. Wakusawa,et al.  [The inhibitory effects of ulinastatin on the increase of interleukin 8 and 6 during open heart surgery]. , 1994, Masui. The Japanese journal of anesthesiology.

[24]  G. von Bernuth,et al.  Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. , 1993, The Journal of thoracic and cardiovascular surgery.

[25]  Ji‐Hyung Park,et al.  Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specific enolase level. , 2003, Archives of neurology.

[26]  David S. Smith,et al.  A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgery. , 1994 .